The development of a recombinant scFv monoclonal antibody targeting canine CD20 for use in comparative medicine

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Jain, Saurabh ^a   Aresu, Luca ^b   Comazzi, Stefano ^c   Shi, Jianguo ^a   Worrall, Erin ^a   Clayton, John ^d   Humphries, William ^d   Hemmington, Sandra ^d   Davis, Paul ^d   Murray, Euan ^a,g   Limeneh, Asmare A ^e   Ball, Kathryn ^a   Ruckova, Eva ^f   Muller, Petr ^f   Vojtesek, Borek ^f   Fahraeus, Robin ^g   Argyle, David ^a   Hupp, Ted R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d Mologic Ltd   (United Kingdom)

^e BAHIR DAR UNIVERSITY   (Ethiopia)

^f MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^g INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CD20 ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY NCD1.2; RECOMBINANT PROTEIN; RECOMBINANT SCFV 3; RECOMBINANT SCFV 7; RITUXIMAB; UNCLASSIFIED DRUG; EPITOPE; HYBRID PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; PEPTIDE; PEPTIDE LIBRARY; PROTEIN BINDING; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MOLECULAR CLONING; MOUSE; NONHUMAN; PHAGE DISPLAY; PROTEIN TARGETING; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; CELL LINE; CHEMISTRY; DOG; GENE EXPRESSION; GENETICS; HYBRIDOMA; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PEPTIDE LIBRARY; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ANTIGENS, CD20; CELL LINE; CLONING, MOLECULAR; DOGS; EPITOPES; GENE EXPRESSION; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; MICE; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; SEQUENCE ALIGNMENT; SINGLE-CHAIN ANTIBODIES;

EID: 84960983838     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148366     Document Type: Article

References (58)

1. Osburn B, Scott C, Gibbs P (2009) One world - one medicine - one health: emerging veterinary challenges and opportunities. Revue scientifique et technique 28: 481-486. PMID: 20128454
2. Calistri P, Iannetti S, M LD, Narcisi V, Cito F, et al. (2013) The components of 'One World - One Health' approach. Transboundary and emerging diseases 60 Suppl 2: 4-13. doi: 10.1111/tbed.12145 PMID: 24589096
3. van Helden PD, van Helden LS, Hoal EG (2013) One world, one health. Humans, animals and the environment are inextricably linked - a fact that needs to be remembered and exploited in our modern approach to health. EMBO reports 14: 497-501. doi: 10.1038/embor.2013.61 PMID: 23681441
4. Torgerson PR (2013) One world health: socioeconomic burden and parasitic disease control priorities. Veterinary parasitology 195: 223-232.
5. Luengo-Fernandez R, Leal J, Gray A, Sullivan R (2013) Economic burden of cancer across the European Union: a population-based cost analysis. The lancet oncology 14: 1165-1174. doi: 10.1016/S1470-2045(13)70442-X PMID: 24131614
6. Mittra J, Tait J (2012) Analysing stratified medicine business models and value systems: innovation-regulation interactions. New biotechnology 29: 709-719.
7. Peldschus K, Ittrich H (2014) Magnetic resonance imaging of metastases in xenograft mouse models of cancer. Methods in molecular biology 1070: 213-222. doi: 10.1007/978-1-4614-8244-4 16 PMID: 24092443
8. Malaney P, Nicosia SV, Dave V (2014) One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer letters 344: 1-12. doi: 10.1016/j.canlet.2013.10.010 PMID: 24157811
9. DasThakur M, Pryer NK, Singh M (2014) Mouse tumour models to guide drug development and identify resistance mechanisms. The Journal of pathology 232: 103-111. doi: 10.1002/path.4285 PMID: 24122209
10. Siolas D, Hannon GJ (2013) Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer research 73: 5315-5319.
11. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nature reviews Drug discovery 3: 711-715. PMID: 15286737
12. Porrello A, Cardelli P, Spugnini EP (2006) Oncology of companion animals as a model for humans. an overview of tumor histotypes. Journal of experimental & clinical cancer research: CR 25: 97-105.
13. Henry CJ, Bryan JN (2013) Not lost in translation: how study of diseases in our pets can benefit them and us. Missouri medicine 110: 216-219. PMID: 23829106
14. Klopfleisch R, Lenze D, Hummel M, Gruber AD (2011) The metastatic cascade is reflected in the transcriptome of metastatic canine mammary carcinomas. Veterinary journal 190: 236-243.
15. Pinho SS, Carvalho S, Cabral J, Reis CA, Gartner F (2012) Canine tumors: a spontaneous animal model of human carcinogenesis. Translational research: the journal of laboratory and clinical medicine 159:165-172.
16. Parker HG, Shearin AL, Ostrander EA (2010) Man's best friend becomes biology's best in show: genome analyses in the domestic dog. Annual review of genetics 44: 309-336. doi: 10.1146/annurev-genet-102808-115200 PMID: 21047261
17. Shearin AL, Ostrander EA (2010) Canine morphology: hunting for genes and tracking mutations. PLoS biology 8: e1000310. doi: 10.1371/journal.pbio.1000310 PMID: 20209140
18. Ranieri G, Gadaleta CD, Patruno R, Zizzo N, Daidone MG, et al. (2013) A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Critical reviews in oncology/hematology 88: 187-197. doi: 10.1016/j.critrevonc.2013.03.005 PMID: 23561333
19. Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, et al. (2006) The dog as a cancer model. Nature biotechnology 24:1065-1066.
20. Sinha G (2014) Companion therapeutics. Nature biotechnology 32: 12-14. doi: 10.1038/nbt.2793 PMID: 24406919
21. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nature reviews Cancer 12: 278-287. doi: 10.1038/nrc3236 PMID: 22437872
22. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature reviews Immunology 10: 317-327. doi: 10.1038/nri2744 PMID: 20414205
23. Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F (2005) CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmunity reviews 4: 526-531. PMID: 16214090
24. Ernst JA, Li H, Kim HS, Nakamura GR, Yansura DG, et al. (2005) Isolation and characterization of the B-cell marker CD20. Biochemistry 44: 15150-15158. PMID: 16285718
25. Griffin MM, Morley N (2013) Rituximab in the treatment of non-Hodgkin's lymphoma - a critical evaluation of randomized controlled trials. Expert opinion on biological therapy 13: 803-811. doi: 10.1517/14712598.2013.786698 PMID: 23560506
26. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, et al. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195. PMID: 9310469
27. Chambers SA, Isenberg D (2005) Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 14: 210-214. PMID: 15807198
28. Sinha A, Bagga A (2013) Rituximab therapy in nephrotic syndrome: implications for patients' management. Nature reviews Nephrology 9: 154-169. doi: 10.1038/nrneph.2012.289 PMID: 23338210
29. Lee S, Ballow M (2010) Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases. The Journal of allergy and clinical immunology 125: 814-820. doi: 10.1016/j.jaci.2010.02.025 PMID: 20371395
30. Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E (2013) Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PloS one 8: e66308. doi: 10.1371/journal.pone.0066308 PMID: 23843952
31. Vo AA, Choi J, Cisneros K, Reinsmoen N, Haas M, et al. (2014) Benefits of Rituximab Combined With Intravenous Immunoglobulin for Desensitization in Kidney Transplant Recipients. Transplantation.
32. Vital EM, Kay J, Emery P (2013) Rituximab biosimilars. Expert opinion on biological therapy 13: 1049-1062. doi: 10.1517/14712598.2013.787064 PMID: 23600760
33. Pouget JP, Navarro-Teulon I, Bardies M, Chouin N, Cartron G, et al. (2011) Clinical radioimmunotherapy - the role of radiobiology. Nature reviews Clinical oncology 8: 720-734. doi: 10.1038/nrclinonc.2011.160 PMID: 22064461
34. Grillo-Lopez AJ (2002) Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert review of anticancer therapy 2: 485-493. PMID: 12382517
35. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, et al. (2002) Ibritumomabtiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99: 4336-4342. PMID: 12036859
36. Ito D, Frantz AM, Modiano JF (2014) Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. Veterinary immunology and immunopathology.
37. Mudaliar MA, Haggart RD, Miele G, Sellar G, Tan KA, et al. (2013) Comparative gene expression profiling identifies common molecular signatures of NF-kappaB activation in canine and human diffuse large B cell lymphoma (DLBCL). PloS one 8: e72591. doi: 10.1371/journal.pone.0072591 PMID: 24023754
38. Ito D, Brewer S, Modiano JF, Beall MJ (2014) Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential. Leukemia & lymphoma.
39. Lane DP, Lane EB (1981) A rapid antibody assay system for screening hybridoma cultures. Journal of immunological methods 47: 303-307. PMID: 7037967
40. Ferraresso S, Bresolin S, Arico A, Comazzi S, Gelain ME, et al. (2014) Epigenetic Silencing of TFPI-2 in Canine Diffuse Large B-Cell Lymphoma. PloS one 9: e92707. doi: 10.1371/journal.pone.0092707 PMID: 24695110
41. Poggi A, Miniscalco B, Morello E, Comazzi S, Gelain ME, et al. (2013) Flow cytometric evaluation of ki67 for the determination of malignancy grade in canine lymphoma. Veterinary and comparative oncology.
42. Comazzi S, Gelain ME (2011) Use of flow cytometric immunophenotyping to refine the cytological diagnosis of canine lymphoma. Veterinary journal 188:149-155.
43. Nathan S, Li H, Mohamed R, Embi N (2002) Phage display of recombinant antibodies toward Burkholderia pseudomallei exotoxin. Journal of biochemistry, molecular biology, and biophysics: JBMBB: the official journal of the Federation of Asian and Oceanian Biochemists and Molecular Biologists 6: 45-53.
44. Bhatia J, Sharma SK, Chester KA, Pedley RB, Boden RW, et al. (2000) Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. International journal of cancer Journal international du cancer 85: 571-577. PMID: 10699932
45. Du J, Wang H, Zhong C, Peng B, Zhang M, et al. (2007) Structural basis for recognition of CD20 by therapeutic antibody Rituximab. The Journal of biological chemistry 282: 15073-15080. PMID: 17395584
46. Perosa F, Favoino E, Vicenti C, Guarnera A, Racanelli V, et al. (2009) Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes. Journal of immunology 182: 416-423.
47. Powers GA, Hudson PJ, Wheatcroft MP (2012) Design and production of multimeric antibody fragments, focused on diabodies with enhanced clinical efficacy. Methods in molecular biology 907: 699-712. doi: 10.1007/978-1-61779-974-7 39 PMID: 22907381
48. Bagshawe KD (2009) Targeting: the ADEPT story so far. Current drug targets 10: 152-157. PMID: 19199911
49. Blakey DC, Davies DH, Dowell RI, East SJ, Burke PJ, et al. (1995) Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. British journal of cancer 72: 1083-1088. PMID: 7577451
50. Siller E, DeZwaan DC, Anderson JF, Freeman BC, Barral JM (2010) Slowing bacterial translation speed enhances eukaryotic protein folding efficiency. J Mol Biol 396:1310-1318.
51. Milenic DE (2002) Monoclonal antibody-based therapy strategies: providing options for the cancer patient. Current pharmaceutical design 8: 1749-1764. PMID: 12171546
52. Ricart AD, Tolcher AW (2007) Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nature clinical practice Oncology 4: 245-255. PMID: 17392715
53. Tobinai K (2003) Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan. Cancer chemotherapy and pharmacology 52 Suppl 1: S90-96. PMID: 12819934
54. Jubala CM, Wojcieszyn JW, Valli VE, Getzy DM, Fosmire SP, et al. (2005) CD20expression in normal canine B cells and in canine non-Hodgkin lymphoma. Veterinary pathology 42: 468-476. PMID: 16006606
55. Nixon AE, Sexton DJ, Ladner RC (2014) Drugs derived from phage display: from candidate identification to clinical practice. MAbs 6: 73-85. PMID: 24262785
56. Doerner A, Rhiel L, Zielonka S, Kolmar H (2014) Therapeutic antibody engineering by high efficiency cell screening. FEBS Lett 588: 278-287. doi: 10.1016/j.febslet.2013.11.025 PMID: 24291259
57. Eisenhardt SU, Schwarz M, Bassler N, Peter K (2007) Subtractive single-chain antibody (scFv) phagedisplay: tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules. Nat Protoc 2: 3063-3073. PMID: 18079705
58. Yang J, Zhu H, Tan Z, He F, Sun X, et al. (2013) Comparison of two functional kappa light-chain transcripts amplified from a hybridoma. Biotechnol Appl Biochem 60: 289-297. doi: 10.1002/bab.1080 PMID: 23631518